Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: testing positive for covid; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (testing positive for covid) in a 71-year-old male patient who received mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (batch no. 3042646) for COVID-19 prophylaxis.     The patient's past medical history included Clinical trial participant (Participated in Johnson and Johnson Covid Clinical trial) on 02-Dec-2020. Previously administered products included for Product used for unknown indication: Johnson and johnson Covid Clinical trial (Dose 1, intramuscular and Johnson and Johnson Covid Clinical trial) on 02-Dec-2020; for COVID-19 prophylaxis: Moderna COVID-19 vaccine (Dose 2) on 14-Jan-2021, Moderna Vaccine (Dose 3) on 11-Feb-2021, Moderna Vaccine (Dose 4) on 22-Oct-2021, Moderna Vaccine (Dose 5) on 20-Mar-2022, Moderna Vaccine (Dose 6) on 04-Sep-2022, Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) (Dose 7) on 20-Apr-2023, Moderna Vaccine (Dose 8) on 16-Sep-2023 and Spikevax 2023-2024 formula (Dose 9) on 07-Mar-2024. Past adverse reactions to the above products included No adverse effect with Johnson and johnson Covid Clinical trial, Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), Moderna COVID-19 vaccine, Moderna Vaccine, Moderna Vaccine, Moderna Vaccine, Moderna Vaccine, Moderna Vaccine and Spikevax 2023-2024 formula. Concurrent medical conditions included Increased blood pressure (under control with medications.), Blood cholesterol increased (under control with medications.) and Seasonal allergy (Seasonal allergies). Concomitant products included Rosuvastatin calcium (Rosuvastatin) for Blood cholesterol increased, Lisinopril for Increased blood pressure, Loratadine (Claritin) for Seasonal allergy, Cyanocobalamin (Vitamin b12) for an unknown indication.    On 07-Sep-2024 at 3:00 PM, the patient received tenth dose of mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Intramuscular use) 1 dosage form. On 22-Feb-2025,  after starting mRNA-1273.712 (SPIKEVAX 2024-2025 PFS), the patient experienced COVID-19 (testing positive for covid). The patient was treated with Nirmatrelvir, Ritonavir (Paxlovid) from 23-Feb-2025 to 28-Feb-2025 at an unspecified dose and frequency. On 26-Feb-2025, COVID-19 (testing positive for covid) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 22-Feb-2025, SARS-CoV-2 test: Positive. On 26-Feb-2025, SARS-CoV-2 test: Negative.         The patient was not allergic to previous vaccination, medications, food, or other products.   The patient did not receive any other vaccines within first 4 weeks prior to the first administration of the suspect vaccine.  It was reported that patient had all Covid-19 vaccinations and boosters and even participated in Clinical trial of Johnson and Johnson vaccine. The patient had avoided getting Covid for four plus years even his wife had it twice.  It was reported that the patient tested positive for Covid on 22-Feb-2025 and it did not require a visit to the Emergency Room or Physician's Office.  Patient took Paxlovid and tested negative for Covid on 26-Feb-2025. The patient again tested positive on 29-Feb-2025 and mild symptoms resolved in few days but had rebound effect. It was reported that cough and headache of patient had resolved and still had allergy symptoms due to seasonal allergies.  No predisposing factors were there and no at risk health issue or exposures.  No culture was performed.   No other relevant tests were reported.   No other antipyretic products used around date of vaccination.